In a brutal first quarter for Roche, key drugs in the company’s pharmaceutical division fall short of Wall Street ...

With Regeneron poised to announce a drug pricing deal with the White House Thursday, all 17 companies targeted in a round of ...

After a series of regulatory and clinical setbacks for Sanofi’s tolebrutinib, the French pharma has scored a victory for the ...

The FDA has doled out two manufacturing-related complete response letters (CRLs), slamming the brakes on prospective ...

Travis Smith was a very serious baby. Born completely unable to hear, his mother, Sierra, struggled to see his personality ...

With the recent launches of Novo Nordisk’s Wegovy pill and Eli Lilly’s Foundayo, the obesity market has started to shift ...

Daiichi Sankyo has postponed its annual report by two weeks to allow for additional time to finalize the financial figures. | ...

During Pfizer's right-sizing push after the COVID-19 pandemic, the company's multibillion-dollar cost-cutting campaign has ...

Normally on Big Pharma earnings calls, execs are eager to talk up their new launches and tout blockbuster expectations. | In ...

The FDA’s new practice of releasing redacted complete response letters (CRLs) in the name of “radical transparency” is ...

Merck & Co. unveiled the much-anticipated first look at its PD-1xVEGF bispecific data. China's Zai Lab is looking to go ...

With the recent launch of Novo Nordisk’s Wegovy pill opening the oral GLP-1 market for obesity, the company has now unveiled ...